All Stories

  1. The Current Landscape of Artificial Intelligence in Positron Emission Tomography (PET) Imaging Across the Cancer Continuum
  2. Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report
  3. A multi-modal approach for decision making in bladder cancer
  4. Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology
  5. Idiopathic Inflammatory Myopathy With Normal Creatine Kinase Levels in an Elderly Patient: A Diagnostic Challenge
  6. Redefining Chemotherapy-Related Headaches: From Pathobiology to Differential Diagnosis and Management
  7. From Crisis to Cancer: Diabetic Ketoacidosis Unmasking a Malignancy of Unknown Origin
  8. Cancer Reversion Therapy: Prospects, Progress and Future Directions
  9. Efficacy of ketogenic metabolic therapy as an adjuvant to the current standard of care in the treatment of glioblastoma: A systematic review of clinical trials
  10. Molecular engines driving biogenesis, trafficking and release of exosomes: SNARE proteins
  11. The risk of lung cancer from vaping or e-cigarette usage: a systematic review
  12. Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review
  13. Resolution of Persistent Fever and Systemic Inflammation in a Metastatic Gastrointestinal Stromal Tumour (GIST) With Imatinib
  14. Advancing circular economy practices in radiography: a narrative review of sustainable medical imaging
  15. Therapeutic opportunities in EBV-positive gastric cancer subtypes
  16. SKP2 at the crossroads of proliferation and immune evasion: a new target in the tumor microenvironment
  17. Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence
  18. Enhancing home rehabilitation through AI-driven virtual assistants: a narrative review
  19. Generative artificial intelligence in predictive analysis of diabetes and its complications: a narrative review
  20. Smart emergency care: a narrative review of predictive machine learning models
  21. Comparative Analysis of Large Language Models in Dermatological Diagnosis: An Evaluation of Diagnostic Accuracy
  22. The evolution of targeted intra operative radiotherapy in early breast cancer
  23. The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
  24. Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer—Guiding Chemotherapy and Predicting Response
  25. Immune Organoids: A Review of Their Applications in Cancer and Autoimmune Disease Immunotherapy
  26. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
  27. Enhancing Parkinson’s disease prediction using meta-heuristic optimized machine learning models
  28. Evaluating AI adoption in healthcare: Insights from the information governance professionals in the United Kingdom
  29. The Impact of AI-Driven Chatbot Assistance on Protocol Development and Clinical Research Engagement: An Implementation Report
  30. Stacked Ensemble Learning for Classification of Parkinson’s Disease Using Telemonitoring Vocal Features
  31. Urban Microclimates and Their Relationship with Social Isolation: A Review
  32. Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis
  33. Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review
  34. Reversing Epigenetic Dysregulation in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations
  35. Disentangling the Gordian Knot of parasympathetic innervations in arthritic joint
  36. AI-Driven Advancements in Orthodontics for Precision and Patient Outcomes
  37. The current landscape of artificial intelligence in computational histopathology for cancer diagnosis
  38. Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
  39. Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment
  40. AI-Driven Advances in Low-Dose Imaging and Enhancement—A Review
  41. Spinal MRI in Patients with Suspected Metastatic Spinal Cord Compression: A Quality Improvement Audit in a District General Hospital in Kent, UK
  42. Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review
  43. Male Breast Cancer: A Single Institutional Clinicopathological Profiling
  44. Enhancing Ophthalmic Diagnosis and Treatment with Artificial Intelligence
  45. Precision oncology through next generation sequencing in hepatocellular carcinoma
  46. Spotlight on Lung Cancer Disparities in India
  47. Molecular biomarkers of glial activation and injury in epilepsy
  48. Integrating AI into Cancer Immunotherapy—A Narrative Review of Current Applications and Future Directions
  49. Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
  50. Molecular Biology of Cancer—Interplay of Malignant Cells with Emerging Therapies
  51. Construction of a prognostic survival model with tumor immune-related genes for breast cancer
  52. An overview of immune checkpoint inhibitor toxicities in bladder cancer
  53. An orthogonal approach for analysis of underivatized steroid hormones using ultrahigh performance supercritical fluid chromatography-mass spectrometry (UHPSFC-MS)
  54. AI-Guided Cancer Therapy for Patients with Coexisting Migraines
  55. Artificial Intelligence – Guided Cancer Therapy for Patients with Migraine Comorbidities
  56. Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer
  57. Paediatric Anatomical Models in Radiotherapy Applications
  58. Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape
  59. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
  60. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
  61. lncRNA Biomarkers of Glioblastoma Multiforme
  62. Large Language Models in Oncology: Revolution or Cause for Concern?
  63. The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer
  64. A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer
  65. A rare case of metaplastic breast carcinoma from India: Towards precision oncology
  66. Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis
  67. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4
  68. Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles
  69. Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
  70. Medical oncology: challenges in 2022
  71. Frontiers of Molecular Biology of Cancer
  72. Immune checkpoint inhibitors in patients with cancers of unknown primary
  73. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness
  74. Frontiers of Ovarian Carcinosarcoma
  75. COVID-19 Associated Mucormycosis and Cytomegalovirus Infection – A Case Report
  76. Renal Cell Cancer – Insights in Drug Resistance Mechanisms
  77. The integration of palliative care with oncology: the path ahead
  78. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
  79. Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
  80. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer—A Retrospective UK Single-Centre Study
  81. Gestational Renal Cell Cancer – An Update
  82. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
  83. Re: Pain and Health-related Quality of Life with Olaparib Versus Physician’s Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An O...
  84. Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer – a Retrospective UK Single-Center Study
  85. Emerging Hallmarks of the Tumour Microenvironment of Gliomas and the Interplay with Immunotherapy
  86. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors
  87. Advances in adoptive T-cell therapy for metastatic melanoma
  88. Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
  89. Impact of COVID-19 on cancer services and patients’ outcomes: a retrospective single-center study
  90. State-of-the-Art Molecular Oncology in UK
  91. Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy
  92. Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
  93. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
  94. Prostate cancer—what about oligometastatic disease and stereotactic ablative radiotherapy?—a narrative review
  95. From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
  96. Constrictive Pericarditis–A Cloak Camouflaging Lymphoma
  97. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
  98. Aberrations of DNA Repair Pathways in Prostate Cancer—The State of the Art
  99. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK
  100. Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
  101. Efficacy and Safety of COVID-19 Vaccines—An Update
  102. A Primary Mediastinal Monophasic Spindle-Cell Synovial Sarcoma with Superior Venacaval Obstruction
  103. Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy
  104. Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
  105. Chromosomal instability in cancers of unknown primary
  106. BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
  107. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
  108. COVID-19, Mucormycosis and Cancer: The Triple Threat—Hypothesis or Reality?
  109. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
  110. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls
  111. Sarcoma of unknown primary: myth or reality?
  112. Systematic review of the CUP trials characteristics and perspectives for next-generation studies
  113. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
  114. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer
  115. Epilepsy and Diagnostic Dilemmas: The Role of Language and Speech-Related Seizures
  116. Metastatic Anorectal Melanoma Presenting as Seizures: An Infrequent Culprit
  117. Case of cerebral venous thrombosis on a patient with background of nephrotic syndrome
  118. Systematic review of fetal and placental metastases among pregnant patients with cancer
  119. Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
  120. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
  121. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
  122. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
  123. The Experience of a Single NHS England Trust on the Impact of the COVID-19 Pandemic on Junior and Middle-Grade Doctors: What Is Next?
  124. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
  125. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
  126. Unraveling the Wide Spectrum of Melanoma Biomarkers
  127. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary
  128. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology
  129. Cancer-Associated Thrombosis: A New Light on an Old Story
  130. Comparative genomic characterization of melanoma of known and unknown primary
  131. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
  132. Management of Metastatic Spinal Cord Compression in Secondary Care: A Practice Reflection from Medway Maritime Hospital, Kent, UK
  133. Melanoma of unknown primary: New perspectives for an old story
  134. Current and future immunotherapy approaches in ovarian cancer
  135. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
  136. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
  137. Metformin and ovarian cancer: the evidence
  138. NOTCH signalling in ovarian cancer angiogenesis
  139. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
  140. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
  141. Ovarian cancer: state of the art and perspectives of clinical research
  142. Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
  143. Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence
  144. An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
  145. Wise Management of Ovarian Cancer: On the Cutting Edge
  146. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
  147. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
  148. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
  149. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
  150. PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
  151. The Developing Story of Predictive Biomarkers in Colorectal Cancer
  152. Ovarian carcinosarcoma: Current developments and future perspectives
  153. Management of Recurrent Uterine Cervical Cancer
  154. Spinal Ewing Sarcoma Debuting with Cord Compression: Have We Discovered the Thread of Ariadne?
  155. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges
  156. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
  157. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature
  158. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
  159. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects
  160. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
  161. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
  162. Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
  163. Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review
  164. Current and future biomarkers in colorectal cancer
  165. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
  166. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies
  167. Cancer specific risk in multiple sclerosis patients
  168. Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence
  169. Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor
  170. Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis
  171. Lung cancer in pregnancy: Report of nine cases from an international collaborative study
  172. Renal cell carcinoma in pregnancy: a rare coexistence